help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Journal of Clinical Endocrinology & Metabolism Vol. 65, No. 3 546-550
doi:10.1210/jcem-65-3-546
Copyright © 1987 by the Endocrine Society.
This Article
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by FARNSWORTH, W. H.
Right arrow Articles by BREWER, H. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by FARNSWORTH, W. H.
Right arrow Articles by BREWER, H. B., JR.

Testicular Function in Type II Hyperlipoproteinemic Patients Treated with Lovastatin (Mevinolin) or Neomycin

W. H. FARNSWORTH, J. M. HOEG, M. MAHER, E. H. BRITTAIN, R. J. SHERINS and H. B. BREWER, JR.

Molecular Disease Branch, National Heart, Lung, and Blood Institute, and the Developmental Endocrinology Branch, National Institute of Child Health and Human Development (R.J.S.), National Institutes of Health Bethesda, Maryland 20892

Address all correspondence and requests for reprints to: W. H. Farnsworth, Molecular Disease Branch, National Heart, Lung, and Blood Institute, Building 10, Room 7N-117, National Institutes of Health, Bethesda, Maryland 20892.

Steroid synthesis requires cholesterol derived from de novo synthesis or plasma lipoproteins. Low density lipoproteins appear to be the major contributor of cholesterol for steroid synthesis in man. Patients with disorders of low density lipoproteins or the low density lipoprotein receptor have reduced cortisol production in response to ACTH. Therapeutic agents designed to lower plasma cholesterol could, therefore, adversely affect steroid hormone production. Lovastatin (mevi-nolin) is a new hypolipidemic agent which blocks cholesterol synthesis by competitive inhibition of 3-hydroxy-3-methylglu-taryl coenzyme A reductase. In beagle dogs, lovastatin at 40–180 times the clinically effective dose in man, has been associated with an increase in spontaneous testicular atrophy. Accordingly, the effect of lovastatin on testicular function and lipoprotein levels was studied in 16 hyperlipidemic men in a randomized, double blind, cross-over study with another hypolipidemic agent, neomycin. Serum testosterone, PRL, LH, and FSH; LHRH-stimulated LH and FSH concentrations; and testicular size were measured, and semen analyses were made. We found no evidence that lovastatin had adverse effects on testicular function despite significant alterations in plasma lipoprotein concentrations.

Received January 14, 1987.




This article has been cited by other articles:


Home page
The Annals of PharmacotherapyHome page
S. A Linnebur and W. H Hiatt
Probable Statin-Induced Testicular Pain
Ann. Pharmacother., January 1, 2007; 41(1): 138 - 142.
[Abstract] [Full Text] [PDF]


Home page
Toxicol PatholHome page
J. S. MacDonald and M. M. Halleck
The Toxicology of HMG--CoA Reductase Inhibitors: Prediction of Human Risk
Toxicol Pathol, February 1, 2004; 32(2_suppl): 26 - 41.
[Abstract] [PDF]


Home page
J. Nutr.Home page
Y. Kido, S. Hiramoto, M. Murao, Y. Horio, T. Miyazaki, T. Kodama, and Y. Nakabou
{epsilon}-Polylysine Inhibits Pancreatic Lipase Activity and Suppresses Postprandial Hypertriacylglyceridemia in Rats
J. Nutr., June 1, 2003; 133(6): 1887 - 1891.
[Abstract] [Full Text] [PDF]


Home page
Toxicol SciHome page
L. A. Dostal, P. Juneau, and C. E. Rothwell
Repeated Analysis of Semen Parameters in Beagle Dogs during a 2-Year Study with the HMG-CoA Reductase Inhibitor, Atorvastatin
Toxicol. Sci., May 1, 2001; 61(1): 128 - 134.
[Abstract] [Full Text] [PDF]


Home page
Toxicol PatholHome page
K. M. Walsh, M. A. Albassam, and D. E. Clarke
Subchronic Toxicity of Atorvastatin, a Hydroxymethylglutaryl-Coenzyme A Reductase Inhibitor, in Beagle Dogs
Toxicol Pathol, July 1, 1996; 24(4): 468 - 476.
[Abstract] [PDF]


Home page
JAMAHome page
J. M. Hoeg and H. B. Brewer Jr
3-Hydroxy-3-Methylglutaryl--Coenzyme A Reductase Inhibitors in the Treatment of Hypercholesterolemia
JAMA, December 25, 1987; 258(24): 3532 - 3536.
[Abstract] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1987 by The Endocrine Society